Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 943 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Woman Showed Up To Their Wedding And Stole All Their Gifts.... March 11, 2019 Immunotherapy Effective in Alveolar Soft Part Sarcoma January 9, 2019 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Digital Breast Tomosynthesis Found to Detect Invasive Cancers At a Higher... December 8, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... For Early-Stage Lung Cancer, Nivolumab and Chemo before Surgery Proves Effective Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell...
